Lupin
Innovation led transnational pharmaceutical company producing a wide range of generic.
Launch date
Employees
Market cap
$13.9b
Enterprise valuation
$14.0b (Public information from Sep 2024)
Share price
INR2151.3501 LUPIN.NS
Mumbai Maharashtra (HQ)
Financials
Estimates*
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.8b | 2.0b | 2.0b | 2.4b | 2.7b | 3.0b | 3.2b |
| % growth | (1 %) | 8 % | - | 21 % | 12 % | 12 % | 6 % |
| EBITDA | 320m | 290m | 231m | 502m | 581m | 694m | 722m |
| % EBITDA margin | 17 % | 15 % | 12 % | 21 % | 21 % | 23 % | 22 % |
| Profit | 150m | (189m) | 53.1m | 236m | 338m | 429m | 455m |
| % profit margin | 8 % | (9 %) | 3 % | 10 % | 12 % | 14 % | 14 % |
| EV / revenue | 3.2x | 2.3x | 2.0x | 3.8x | 4.7x | 4.1x | 3.8x |
| EV / EBITDA | 18.4x | 15.6x | 17.3x | 18.5x | 21.8x | 18.0x | 17.0x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
$50.0m | Post IPO Equity | ||
| Total Funding | - | ||
Related Content
Recent News about Lupin
EditInvestments by Lupin
Edit
ACQUISITION by Lupin Jul 2015
ACQUISITION by Lupin Jul 2015
ACQUISITION by Lupin Oct 2017
ACQUISITION by Lupin Jul 2015
ACQUISITION by Lupin Jul 2015
ACQUISITION by Lupin Feb 2014
ACQUISITION by Lupin May 2015
ACQUISITION by Lupin Mar 2015
ACQUISITION by Lupin May 2023